Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H14N3O3.Br.BrH |
| Molecular Weight | 397.063 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.[Br-].N[C@]2(C[N+]1=CC=CC=C1)C[C@@H](NC2=O)C(O)=O
InChI
InChIKey=GIZKBHWITTWBAP-IEQXMABBSA-N
InChI=1S/C11H13N3O3.2BrH/c12-11(7-14-4-2-1-3-5-14)6-8(9(15)16)13-10(11)17;;/h1-5,8H,6-7,12H2,(H-,13,15,16,17);2*1H/t8-,11+;;/m1../s1
| Molecular Formula | C11H13N3O3 |
| Molecular Weight | 235.2392 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:40:07 GMT 2025
by
admin
on
Tue Apr 01 16:40:07 GMT 2025
|
| Record UNII |
869R8A3UZS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
953074-84-5
Created by
admin on Tue Apr 01 16:40:07 GMT 2025 , Edited by admin on Tue Apr 01 16:40:07 GMT 2025
|
PRIMARY | |||
|
300000010720
Created by
admin on Tue Apr 01 16:40:07 GMT 2025 , Edited by admin on Tue Apr 01 16:40:07 GMT 2025
|
PRIMARY | |||
|
24826985
Created by
admin on Tue Apr 01 16:40:07 GMT 2025 , Edited by admin on Tue Apr 01 16:40:07 GMT 2025
|
PRIMARY | |||
|
869R8A3UZS
Created by
admin on Tue Apr 01 16:40:07 GMT 2025 , Edited by admin on Tue Apr 01 16:40:07 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Laboratoires Prodimed; Class: Amino acid, Antineoplastic, Pyridinium compound; Mechanism of Action: Immunomodulator; Orphan Drug Status: Yes for Renal cancer; Highest Development Phase: Phase I for Solid tumours; Most Recent Event: 11 Jul 2011 Phase-I clinical trials in Solid tumours in Spain (unspecified route)
|